Professor Allan Wailoo

All publications

Journal articles

• Hernández Alava M, Pudney SE & Wailoo AJ (2023) Does EQ-5D tell the whole story? Statistical methods for comparing the thematiccoverage of clinical and generic outcome measures, with application to breast cancer. Value in Health.
• Gray LA, Hernandez Alava M & Wailoo AJ (2022) Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer, 22(1).
• Hussain H, Keetharuth A, Rowen D & Wailoo A (2022) Convergent validity of EQ-5D with core outcomes in dementia: a systematic review. Health and Quality of Life Outcomes, 20(1). View this article in WRRO
• Girling C, Lee MJ, Vimalchandran D, Jayne DJ, Stancliffe S, Wailoo A, Bradburn M, Hind D, Bursnall M, Robinson LK & Brown SR (2022) Protocol for the ORION trial (RadiO fRequency ablatION for haemorrhoids): a randomised controlled trial. Techniques in Coloproctology. View this article in WRRO
• Peasgood T, Mukuria C, Rowen D, Tsuchiya A & Wailoo A (2022) Should we consider including a value for "Hope" as an additional benefit within health technology assessment?. Value in Health. View this article in WRRO
• Rowen D, Wickramasekera N, Hole A, Keetharuth D & Wailoo A (2022) A discrete choice experiment to elicit general population preferences around the factors influencing the choice to make clinical negligence claims. Value in Health. View this article in WRRO
• Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A & Grieve R (2022) Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real-world data : opportunities and challenges. PharmacoEconomics. View this article in WRRO
• Scott DL, Ibrahim F, Hill H, Tom B, Prothero L, Baggott RR, Bosworth A, Galloway JB, Georgopoulou S, Martin N , Neatrour I et al (2021) Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. Programme Grants for Applied Research, 9(8). View this article in WRRO
• Wailoo A, Alava MH, Pudney S, Barton G, O’Dwyer J, Gomes M, Irvine L, Meads D & Sadique Z (2021) An international comparison of EQ-5D-5L and EQ-5D-3L for use in cost-effectiveness analysis. Value in Health.
• Rowen D, Keetharuth D, Poku E, Wong R, Pennington R & Wailoo A (2020) A review of the psychometric performance of selected child and adolescent preference-based measures used to produce utilities for child and adolescent health. Value in Health. View this article in WRRO
• Scott D, Ibrahim F, Hill H, Tom B, Prothero L, Baggott RR, Bosworth A, Galloway JB, Georgopoulou S, Martin N , Neatrour I et al (2020) The clinical effectiveness of intensive management in moderate established rheumatoid arthritis : the titrate trial. Seminars in Arthritis and Rheumatism, 50(5), 1182-1190. View this article in WRRO
• Hernandez M, Wailoo A, Chrysanthou G, Carvalho P, Van der Heijde D, Santos MJ & Machado PM (2020) OP0078 MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 79(Suppl 1), 52.1-53.
• Hill J, Pennington R, Wailoo A, Wong R & Rowen D (2020) A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health. View this article in WRRO
• Hernandez Alava M, Pudney S & Wailoo A (2020) The EQ-5D-5L value set for England: Findings of a quality assurance program. Value in Health. View this article in WRRO
• Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Embleton N, Graham R, Hart AR, Jarvis D, Kilby MD, Lie M , Mason G et al (2019) MRI in the diagnosis of fetal developmental brain abnormalities : the MERIDIAN diagnostic accuracy study. Health Technology Assessment, 23(49), 1-144. View this article in WRRO
• Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, Augustovski F, Booth A, Bridges JFP, Grimshaw J , IJzerman MJ et al (2019) Identifying the need for good practices in health technology assessment: Summary of the ISPOR HTA council working group report on good practices in HTA. Value in Health, 22(1), 13-20. View this article in WRRO
• (2018) United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 38(4), 314-314.
• Gray LA, Wailoo A & Hernandez M (2018) Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping. Value in Health. View this article in WRRO
• Pennington B, Hernandez-Alava M, Pudney S & Wailoo A (2018) The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. PharmacoEconomics. View this article in WRRO
• Gray LA, Hernandez M & Wailoo AJ (2018) Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. Value in Health, 21(6), 748-757. View this article in WRRO
• Shah K, Tsuchiya A & Wailoo A (2018) Valuing health at the end of life: A review of stated preference studies in the social sciences literature. Social Science & Medicine, 204, 39-50. View this article in WRRO
• Simpson EL, Hock E, Stevenson M, Wong R, Dracup N, Wailoo A, Conaghan PG, Estrach C, Edwards CJ & Wakefield RJ (2018) What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment, 22(20). View this article in WRRO
• Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, Meads D, O’Dwyer J, Barton G & Irvine L (2018) EQ-5D-5L versus EQ-5D-3L: The Impact on Cost-Effectiveness in the United Kingdom. Value in Health, 21(1), 49-56. View this article in WRRO
• Martin NH, Ibrahim F, Tom B, Galloway J, Wailoo A, Tosh J, Lempp H, Prothero L, Georgopoulou S, Sturt J , Scott DL et al (2017) Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials, 18(1), 591-591. View this article in WRRO
• Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC & Wailoo A (2017) Use of MRI in the Diagnosis of Fetal Brain Abnormalities in Utero (MERIDIAN). Obstetric Anesthesia Digest, 37(4), 202-203.
• Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL & Young A (2017) The clinical effectiveness and Cost-Effectiveness of Treat-To-Target strategies in rheumatoid arthritis: A systematic review and cost-effectiveness analysis. Health Technology Assessment, 21(71), 1-258. View this article in WRRO
• Grimm SE, Strong M, Brennan A & Wailoo A (2017) The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. PharmacoEconomics, 35(12), 1287-1296. View this article in WRRO
• Briggs V, Solis-Trapala I, Wailoo A, McCullough K, Lambie M, Caskey FJ, Fotheringham J, Davies SJ & Wilkie M (2017) United Kingdom Catheter Study- Protocol Synopsis. Peritoneal Dialysis International. View this article in WRRO
• Gullick NJ, Mian AN, Ibrahim F, Walker D, Hassell A, Kiely PDW, Walsh DA, Young A, Scott DL, Lempp H , Sturt J et al (2017) Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data. Clinical and Experimental Rheumatology, 35(5), 810-815.
• Johannesen KM, Claxton K, Sculpher MJ & Wailoo AJ (2017) How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework. Health Economics. View this article in WRRO
• Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A & Scott DL (2017) The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. Journal of Rheumatology, 44(7), 973-980. View this article in WRRO
• Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC & Wailoo A (2017) Use of MRI in the Diagnosis of Fetal Brain Abnormalities in Utero (MERIDIAN). Obstetrical & Gynecological Survey, 72(6), 323-325.
• Griffiths PD, Bradburn M, Campbell MJ, Connolly DJA, Cooper CL, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC & Wailoo A (2017) Change in diagnostic confidence brought about by using in utero MRI for fetal structural brain pathology: Analysis of the MERIDIAN cohort. Clinical Radiology. View this article in WRRO
• Alshreef A, Wailoo AJ, Brown SR, Tiernan JP, Watson AJM, Biggs CE, Bradburn M & Hind D (2017) Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial. PharmacoEconomics Open. View this article in WRRO
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method. Statistical Methods in Medical Research, 26(2), 724-751.
• Wailoo AJ, hernandez M, manca A, mejia A, Ray J, crawford B, botteman M & busschbach J (2017) Mapping to Estimate Health-State Utility from Non–Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 20(1), 18-27. View this article in WRRO
• Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC , Wailoo A et al (2016) Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. The Lancet, 389(10068), 538-546. View this article in WRRO
• Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 20(90). View this article in WRRO
• Brown S, Tiernan J, Biggs K, Hind D, Shephard N, Bradburn M, Wailoo A, Alshreef A, Swaby L, Watson A , Radley S et al (2016) The HubBle trial: Haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: A multicentre randomized controlled trial and health-economic evaluation. Health Technology Assessment, 20(88), 1-180. View this article in WRRO
• Franklin M, Wailoo A, Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB & Thornhill MH (2016) The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis. Circulation, 134(20), 1568-1578. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 611-614.
• Brown SR, Tiernan JP, Watson AJM, Biggs K, Shephard N, Wailoo AJ, Bradburn M, Alshreef A & Hind D (2016) Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. The Lancet, 388(10042), 356-364. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
• Madan J, Ades T, Barton P, Bojke L, Choy E, Helliwell P, Jobanputra P, Stein K, Stevens A, Tosh J , Verstappen S et al (2015) Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2(2), 113-125. View this article in WRRO
• Wailoo A, Hernández M, Philips C, Brophy S & Siebert S (2015) Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. Value in Health, 18(4), 425-431.
• Shah KK, Tsuchiya A & Wailoo AJ (2015) Valuing health at the end of life: A stated preference discrete choice experiment. Social Science & Medicine, 124, 48-56. View this article in WRRO
• Skedgel C, Wailoo A & Akehurst R (2015) Societal Preferences for Distributive Justice in the Allocation of Health Care Resources. Medical Decision Making, 35(1), 94-105.
• Skedgel CD, Wailoo AJ & Akehurst RL (2015) Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences.. Health Expect, 18(5), 1227-1240. View this article in WRRO
• Alava MH & Wailoo A (2015) Fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal: Promoting communications on statistics and Stata, 15(3), 737-750. View this article in WRRO
• Wailoo A, Hernández Alava M, Scott IC, Ibrahim F & Scott DL (2014) Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.. Rheumatology (Oxford), 53(10), 1773-1777.
• Norton S, Fu B, Scott DL, Deighton C, Symmons DPM, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A & Verstappen SMM (2014) Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.. Semin Arthritis Rheum, 44(2), 131-144. View this article in WRRO
• Hernández Alava M, Wailoo A, Wolfe F & Michaud K (2014) A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.. Med Decis Making, 34(7), 919-930.
• Poku E, Rathbone J, Everson-Hock E, Essat M, Wong R, Pandor A & Wailoo A (2014) The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open, 4. View this article in WRRO
• Shah KK, Tsuchiya A & Wailoo AJ (2014) Valuing health at the end of life: an empirical study of public preferences.. Eur J Health Econ, 15(4), 389-399.
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.. Med Decis Making, 34(3), 387-402.
• Wailoo A, Hernandez Alava M & Escobar Martinez A (2014) Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D.. Health Qual Life Outcomes, 12, 37. View this article in WRRO
• Houten R, Wailoo A, Jonsson P & McLeod C (2014) Variations in primary care prescribing: lessons to be learnt for GP commissioners.. Prim Health Care Res Dev, 15(1), 111-116.
• Johannesen KM, Claxton K, Sculpher MJ & Wailoo AJ (2013) COMPARING THE VALUE OF DIFFERENT HTA DECISION MAKING PROCESS: EVALUATING THE EVALUATORS. VALUE IN HEALTH, 16(7), A489-A489.
• Wailoo AJ, Hernandez M & Escobar Martinez A (2013) MODELLING THE RELATIONSHIP BETWEEN THE WO MAC OSTEOARTHRITIS INDEX AND EQ-5D. VALUE IN HEALTH, 16(7), A606-A606.
• Kearns B, Ara R, Wailoo A, Manca A, Alava MH, Abrams K & Campbell M (2013) Good practice guidelines for the use of statistical regression models in economic evaluations.. Pharmacoeconomics, 31(8), 643-652.
• Hernández Alava M, Wailoo A, Wolfe F & Michaud K (2013) The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.. Rheumatology (Oxford), 52(5), 944-950. View this article in WRRO
• Davis S & Wailoo A (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence.. Health Qual Life Outcomes, 11, 20. View this article in WRRO
• Ara R & Wailoo AJ (2013) Estimating health state utility values for joint health conditions: a conceptual review and critique of the current evidence.. Med Decis Making, 33(2), 139-153.
• Tiernan J, Hind D, Watson A, Wailoo AJ, Bradburn M, Shephard N, Biggs K & Brown S (2012) The HubBLe trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for haemorrhoids.. BMC Gastroenterol, 12, 153. View this article in WRRO
• Scott IC, Wailoo A & Scott DL (2012) Payers' views on treating-to-target in rheumatoid arthritis: an English perspective.. Clin Exp Rheumatol, 30(4 Suppl 73), S85-S90.
• Ara R & Wailoo A (2012) Using health state utility values in models exploring the cost-effectiveness of health technologies.. Value Health, 15(6), 971-974.
• Hernández Alava M, Wailoo AJ & Ara R (2012) Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.. Value Health, 15(3), 550-561.
• Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A , Jeffreys M et al (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.. Health Technol Assess, 16(21), 1-470.
• Shah K, Wailoo AJ & Tsuchiya A (2011) Valuing Health at the End of Life: An Exploratory Preference Elicitation Study.
• Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.. BMC Med Res Methodol, 11, 4. View this article in WRRO
• Sampson F, Goodacre S, Carter A & Wailoo A (2011) Improving call-to-balloon times for ST-elevation myocardial infarction. Journal of Paramedic Practice, 3(11), 625-631.
• Wailoo AJ, Hernandez M & Ara R (2011) MODELLING EQ-5D HEALTH STATE VALUES: DEVELOPING A LIMITED DEPENDENT VARIABLE, MIXTURE MODELING APPROACH. VALUE IN HEALTH, 14(7), A242-A242.
• Ara R & Wailoo AJ (2011) A LITERATURE REVIEW OF METHODS USED TO ESTIMATE MEAN PREFERENCE-BASED UTILITIES FOR COMORBIDITIES USING PUBLISHED SUMMARY STATISTICS. VALUE IN HEALTH, 14(7), A425-A425.
• Tosh J, Brennan A, Wailoo A & Bansback N (2011) The Sheffield rheumatoid arthritis health economic model.. Rheumatology (Oxford), 50 Suppl 4, iv26-iv31.
• Melandri G (2011) The cost-effectiveness of primary angioplasty. Heart, 97(2), 163-163.
• Tosh JC, Wailoo AJ, Scott DL & Deighton CM (2011) Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.. J Rheumatol, 38(8), 1593-1600.
• Wailoo A, Goodacre S & Sampson F (2011) The cost-effectiveness of primary angioplasty reply. HEART, 97(2), 163-163.
• Hind D, Wailoo AJ & Sutcliffe P (2011) Demands for 'off-licence' access to trastuzumab (Herceptin): content analysis of UK newspaper articles.. Health Expect, 14(1), 38-47.
• Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ & Scott D (2010) The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.. Rheumatology (Oxford), 49(12), 2313-2321. View this article in WRRO
• Wailoo A, Goodacre S, Sampson F, Alava MH, Asseburg C, Palmer S, Sculpher M, Abrams K, de Belder M & Gray H (2010) Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project.. Heart, 96(9), 668-672.
• Wailoo A, Sutton A & Morgan A (2009) The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.. Br J Cancer, 100(3), 436-441. View this article in WRRO
• Wailoo A, Tsuchiya A & McCabe C (2009) Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected.. Pharmacoeconomics, 27(12), 983-989.
• Wailoo A, Bansback N & Chilcott J (2008) Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply. RHEUMATOLOGY, 47(10), 1590-1590.
• Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM & Wolfe F (2008) Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.. Arthritis Rheum, 58(4), 939-946.
• Cheater FM, Baker R, Gillies C, Wailoo A, Spiers N, Reddish S, Robertson N & Cawood C (2008) The nature and impact of urinary incontinence experienced by patients receiving community nursing services: a cross-sectional cohort study.. Int J Nurs Stud, 45(3), 339-351.
• Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A & Nicholson KG (2008) Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza.. Value Health, 11(2), 160-171.
• Wailoo A, Bansback N & Chilcott J (2008) Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.. Rheumatology (Oxford), 47(2), 119-120.
• Oluboyede Y, Goodacre S, Wailoo A & ESCAPE Research Team (2008) Cost effectiveness of chest pain unit care in the NHS.. BMC Health Serv Res, 8, 174. View this article in WRRO
• Dolan P, Edlin R, Tsuchiya A & Wailoo A (2007) It ain't what you do, it's the way that you do it: Characteristics of procedural justice and their importance in social decision-making. J ECON BEHAV ORGAN, 64(1), 157-170.
• Goodacre S, Stevenson M, Wailoo A, Sampson F, Sutton AJ & Thomas S (2006) Optimal algorithm for evaluating suspected DVT. J FAM PRACTICE, 55(9), 754-754.
• Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A , O'Hagan A et al (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. HEALTH TECHNOL ASSES, 10(24), 1-+.
• Cheater FM, Baker R, Reddish S, Spiers N, Wailoo A, Gillies C, Robertson N & Cawood C (2006) Cluster randomized controlled trial of the effectiveness of audit and feedback and educational outreach on improving nursing practice and patient outcomes.. Med Care, 44(6), 542-551.
• Goodacre S, Stevenson M, Wailoo A, Sampson F, Sutton AJ & Thomas S (2006) How should we diagnose suspected deep-vein thrombosis?. QJM, 99(6), 377-388.
• Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, Locker T & Ryan A (2006) Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.. Health technology assessment (Winchester, England), 10(15).
• Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR & Nicholson KG (2006) The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.. Vaccine, 24(7), 1035-1043.
• Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A , O'Hagan A et al (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.. Health technology assessment (Winchester, England), 10(24).
• Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, Locker T & Ryan A (2006) Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment, 10(15). View this article in WRRO
• Wailoo A & Anand P (2005) The nature of procedural preferences for health-care rationing decisions.. Soc Sci Med, 60(2), 223-236.
• Tsuchiya A, Miguel LS, Edlin R, Wailoo A & Dolan P (2005) Procedural justice in public health care resource allocation.. Appl Health Econ Health Policy, 4(2), 119-127.
• Littlejohns P, Leng G, Culyer T & Drummond M (2004) NICE clinical guidelines: Maybe health economists should participate in guideline development. BMJ, 329(7465), 571.1-571.1.
• Wailoo A, Roberts J, Brazier J & McCabe C (2004) Efficiency, equity, and NICE clinical guidelines. British Medical Journal, 328(7439), 536-537. View this article in WRRO
• Littlejohns P, Leng G, Culyer T, Drummond M, Pilling S, Dutchak J, McInnes E, Macbeth F, Pearson M, Thomas J , Turnbull N et al (2004) NICE clinical guidelines [2] (multiple letters). British Medical Journal, 329(7465), 571-572. View this article in WRRO
• Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ & Burchill SA (2004) A systematic review of molecular and biological tumor markers in neuroblastoma.. Clin Cancer Res, 10(1 Pt 1), 4-12.
• Wailoo AJ, Turner D, Cooper N, Sutton A, Abrams K & Nicholson K (2003) Cost-effectiveness and value of information analyses of the use of antivirals for the treatment of influenza in healthy adults. VALUE HEALTH, 6(6), 755-755.
• Dolan P, Tsuchiya A & Wailoo A (2003) NICE's citizen's council: what do we ask them, and how?. LANCET, 362(9387), 918-919.
• Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner DA & Nicholson KG (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BRIT MED J, 326(7401), 1235-+.
• Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A & Abrams K (2003) Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.. Health technology assessment (Winchester, England), 7(35).
• Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ & Lewis IJ (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.. Health technology assessment (Winchester, England), 7(5), 1-162.
• Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A & Abrams K (2003) Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment, 7(35).
• Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ & Lewis IJ (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technology Assessment, 7(5).
• Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ & Lewis IJ (2003) A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.. Eur J Cancer, 39(1), 19-30.
• Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ & Lewis IJ (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.. Health Technol Assess, 7(5), 1-162.
• Shields MA & Wailoo A (2002) Exploring the determinants of unhappiness for ethnic minority men in Britain. SCOT J POLIT ECON, 49(4), 445-466.
• Anand P & Wailoo A (2000) Utilities versus rights to publicly provided goods: Arguments and evidence from health care rationing. ECONOMICA, 67(268), 543-577.
• Hill H, Rawdin A, Wailoo A, Briggs V, Lambie M, McCullough K, Dunn L, Davies S, Wilkie M & Fotheringham J () The clinical implications and cost-effectiveness of the provision of medical in addition to surgical catheter insertion for peritoneal dialysis in people with kidney failure. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis.
• Wickramasekera N, Hole AR, Rowen D, Wailoo A & Keetharuth AD () Exploring the factors that drive clinical negligence claims: stated preferences of those who have experienced unintended harm. Patient: Patient-Centered Outcomes Research. View this article in WRRO
• Hernández Alava M, Pudney S & Wailoo A () Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. PharmacoEconomics.
• Keetharuth D, Hussain H, Rowen D & Wailoo A () Assessing the psychometric performance of EQ-5D-5L in dementia: a systematic review. Health and Quality of Life Outcomes. View this article in WRRO
• Peasgood T, Mukuria C, Rowen D, Tsuchiya A & Wailoo A () Should we consider including a value for ‘hope’ as an additional benefit within HTA?. Value in Health. View this article in WRRO
• Hernández Alava M, Wailoo A, Pudney S, Gray L & Manca A () Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technology Assessment, 24(34), 1-68. View this article in WRRO
• Cox M, O’Connor C, Biggs K, Hind D, Bortolami O, Franklin M, Collins B, Walters S, Wailoo A, Channell J , Albert P et al () The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation. Health Technology Assessment, 22(11), 1-204. View this article in WRRO
• Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A & Moore D () A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technology Assessment, 10(20).
• Hock ES, Martyn-St James M, Wailoo A, Scott DL, Stevenson M, Rawdin A, Simpson EL, Dracup N & Young A () Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Comprehensive Clinical Medicine.
• Gray L, Hernandez M & Wailoo A () Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer.
• Wailoo A, Hernandez M, Chrysanthou G, Barcelos F, van Gaalen F, Santos H, Fagerli K, Gago L, Margarida Cunha M, van de Sande M , Couto M et al () MEASURING QUALITY OF LIFE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOR ECONOMIC EVALUATION. RMD Open.
• Rafia R, Metry A & Wailoo A () A cost-effectiveness analysis of remdesivir for the treatment of hospitalised patients with COVID-19 in England and Wales. Value in Health.
• Rowen D, Mukuria C, Powell P & Wailoo A () Exploring the issues of valuing child and adolescent health states using a mixed sample of adolescents and adults. PharmacoEconomics.

Chapters

• Scott DL & Wailoo A (2020) Health economics of rheumatoid arthritis, Oxford Textbook of Rheumatoid Arthritis (pp. 259-270). Oxford University Press
• Wailoo A (2010) Primary Angioplasty in Health Care Delivery, Clinical Guide to Primary Angioplasty (pp. 179-182). CRC Press
• Wailoo AJ (2010) Primary Angioplasty in Health Care Delivery: The Economics, CLINICAL GUIDE TO PRIMARY ANGIOPLASTY (pp. 179-182).

Conference proceedings papers

• Hussain H, Keetharuth A, Rowen D & Wailoo A (2023) Convergent validity of EQ-5D with core outcomes in dementia: a systematic review. QUALITY OF LIFE RESEARCH, Vol. 32(SUPPL 1) (pp S10-S10)
• Powell P, Rowen D, Mukuria C, Keetharuth A & Wailoo A (2022) Valuing health-related quality of life in children and adolescents: Who should we ask and how? A study protocol for consulting the public and experts in health valuation. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S146-S146)
• Metry A, Rafia R & Wailoo A (2022) ECONOMIC EVALUATION OF NEUTRALISING MONOCLONAL ANTIBODIES FOR THE TREATMENT OF COVID-19 POSITIVE PEOPLE IN THE COMMUNITY. VALUE IN HEALTH, Vol. 25(7) (pp S395-S395)
• Hill H, Rowen D, Pennington B, Wong R & Wailoo A (2019) Are child and adolescent-specific measures used to inform resource allocation decisions? A review of the methods used to generate utility values in NICE technology appraisals for children and adolescents. QUALITY OF LIFE RESEARCH, Vol. 28 (pp S110-S110)
• Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018.
• Alshreef A & Wailoo A (2017) Haemorrhoidal Artery Ligation Procedure For The Treatment of Symptomatic Grade II–III Heamorrhoids: A Trial-Based And Long-Term Model-Based Economic Evaluation. Value in Health, Vol. 20(9) (pp A666-A666)
• Luqmani RA, Lee E, Singh S, Gillett M, Schmidt W, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) ULTRASOUND COMPARED WITH BIOPSY IN THE DIAGNOSIS OF SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 37-37)
• Luqmani RA, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W , Masters S et al (2016) INTERRATER AND INTRARATER ANALYSIS OF ULTRASOUND AND HISTOLOGICAL FINDINGS IN PATIENTS WITH SUSPECTED GIANT CELL ARTERITIS. RHEUMATOLOGY, Vol. 55 (pp 171-171)
• Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, everson HE, Scott D, Young A , Paisley S et al (2014) The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in Health, Vol. 17(7) (pp A380-A380)
• Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) ADJUSTING FOR TREATMENT SWITCHING IN CLINICAL TRIALS WHEN ONLY SUMMARY DATA ARE AVAILABLE - AN EVALUATION OF POTENTIAL METHODS. VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
• Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS. VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
• Norton S, Fu B, Verstappen SMM, Symmons DPM, Lunt M, Davies R, Scott DL, Deighton C, Wailoo AJ, Tosh J & Young A (2013) COMMON TRAJECTORIES OF HAQ DISABILITY PROGRESSION OVER 15-YEARS IN THE EARLY RHEUMATOID ARTHRITIS STUDY AND THE NORFOLK ARTHRITIS REGISTER. ANNALS OF THE RHEUMATIC DISEASES, Vol. 71 (pp 508-508)
• Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
• Tosh J & Wailoo A (2009) COMBINATION DMARDS FOR RHEUMATOID ARTHRITIS: A COST-EFFECTIVENESS ANALYSIS. RHEUMATOLOGY, Vol. 48 (pp I68-I69)
• Cooper NJ, Sutton AJ, Abrams KR, Turner D & Wailoo A (2004) Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. HEALTH ECONOMICS, Vol. 13(3) (pp 203-226)

Reports

• Keetharuth A, Wong R, Hill J, Rowen D & Wailoo A (2023) Health related quality of life in economic evaluations in dementia: state of play and reflections
• Donna R, Brazier J, Hill H, Keetharuth A, Mukuria C, Peasgood T, Wailoo A, Wong R & Hill J (2022) Scoping, assessing feasibility, preliminary research and prioritising projects for the outcome measurement and valuation
• Hill H, Rowen D, Keetharuth A, Wailoo A & Hill J (2022) A literature review of methods to measure and value benefits in cost-effectiveness analyses of interventions for patients with either a short life expectancy or receiving palliative care’
• Rowen D, Mukuria C, Powell P, Wong R & Wailoo A (2021) Valuing child health: Exploring the use of a mixed sample of adolescents and adults to value child and adolescent health states
• Rowen D, Brazier J, Wong R & Wailoo A (2020) Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available
• Rowen D, Keetharuth D, Poku E, Wailoo A, Wong R, Pennington R & Brazier J (2019) A review of the psychometric performance of paediatric preference-based measures used to generate utility values for children
• Hill JH, Rowen D, Pennington R, Wailoo A & Wong R (2019) A review of the methods used to generate utility values in NICE technology appraisals for paediatrics

Scholarly editions

• Hernández-Alava M, Sampson C & Wailoo A (2013) Happy and healthy: a joint model of health and life satisfaction.
• Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P & Wailoo A A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence.
• Anand P & Wailoo A Utilities vs. Rights to Publicly Provided Goods: Arguments and Evidence from Health-Care Rationing.
• Shields M & Wailoo A Unhappiness and Involuntary Unemployment: The Case of Ethnic Minority Men in Britain.

Posters

• Poku E, Rathbone J, Hock E, Essat M, Wong R, Pandor A & Wailoo A (2013) Safety of intravitreal bevacizumab as a monotherapy in ophthalmic conditions: systematic review. Health Technology Assessment International.
• Ara R & Wailoo A A review of methods used to estimate mean preference-based utilities for comorbidities using published summary statistics.
• ALAVA MH & Wailoo A Estimating EQ-5D health states values for Rheumatoid Arthritis patients: a limited dependent variable, mixture modelling approach (2012).

Preprints

• Shah K, Tsuchiya A, Hole AR & Wailoo AJ () Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment.
• Shah K, Wailoo AJ & Tsuchiya A () Valuing Health at the End of Life: An Exploratory Preference Elicitation Study.